A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Back to Search
Print
Bookmark Trial

NCT02187744

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Compassionate Cancer Care Medical Group, Inc.
Fountain Valley, California, 92708, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Early Breast Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed HER2 overexpressing invasive breast cancer.

- Plan for definitive surgical resection of breast tumor (i.e., lumpectomy or mastectomy, and sentinel node (SN) biopsy or axillary lymph node dissection (ALND).

- Plan for neoadjuvant chemotherapy.

- Measurable disease in the breast after diagnostic biopsy, defined as longest diameter ≥ 2.0 cm.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Bilateral breast cancer.


- Inflammatory breast cancer.


- Presence of known distant metastases.


- Received prior treatment, including chemotherapy, endocrine therapy, biologic therapy,
radiation or surgery with the exception of diagnostic biopsy for primary breast
cancer.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Early Breast CancerA Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
NCT02187744
  1. Fountain Valley, California
  2. Kingwood, Texas
  3. Shenandoah, Texas
  4. Shenandoah, Texas
  5. Lesnoy, Minsk Region
  6. Hradec Kralove,
  7. Kecskemet, Bacs-kiskun
  8. Budapest,
  9. Budapest,
  10. Budapest,
  11. Miskolc,
  12. Szolnok,
  13. Milano, MI
  14. Roma, RM
  15. Roma, RM
  16. Roma, RM
  17. Gdynia,
  18. Lodz,
  19. Olsztyn,
  20. Kuzmolovo, Leningrad Region
  21. Ufa, Republic Bashkortost
  22. Kislino Settlement, Ryshkovskiy Village Council
  23. Pyatigorsk, Stavropol Region
  24. Volzhskiy, Volgograd Region
  25. Irkutsk,
  26. Kursk,
  27. Moscow,
  28. Moscow,
  29. Nizhniy Novgorod,
  30. Nizhniy Novgorod,
  31. Omsk,
  32. Saint-Petersburg,
  33. Saint-Petersburg,
  34. Saint-Petersburg,
  35. Saint-Petersburg,
  36. Saint-Petersburg,
  37. Saint-Petersburg,
  38. Velikiy Novgorod,
  39. Belgrade,
  40. Bratislava,
  41. Bratislava,
  42. Kosice,
  43. Chernihiv,
  44. Dnipropetrovsk,
  45. Kharkiv,
  46. Kharkiv,
  47. Khmelnytskyi,
  48. Kryvyi Rih,
  49. Lviv,
  50. Odesa,
  51. Sumy,
  52. Vinnytsia,
Female
18 Years+
years
MULTIPLE SITES
Early Breast CancerEvaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
NCT01155063
Female
18 Years+
years
MULTIPLE SITES
Early Breast CancerTalazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer
NCT03499353
  1. Laguna Hills, California
  2. Mobile, Alabama
  3. Gilbert, Arizona
  4. Gilbert, Arizona
  5. Fayetteville, Arkansas
  6. Rogers, Arkansas
  7. Camarillo, California
  8. Duarte, California
  9. Duarte, California
  10. Fountain Valley, California
  11. Fountain Valley, California
  12. Fountain Valley, California
  13. Glendale, California
  14. Long Beach, California
  15. Long Beach, California
  16. Orange, California
  17. Orange, California
  18. Oxnard, California
  19. Redlands, California
  20. Stanford, California
  21. Stanford, California
  22. Stanford, California
  23. Ventura, California
  24. West Covina, California
  25. Whittier, California
  26. Whittier, California
  27. Aurora, Colorado
  28. Boulder, Colorado
  29. Colorado Springs, Colorado
  30. Denver, Colorado
  31. Denver, Colorado
  32. Englewood, Colorado
  33. Lakewood, Colorado
  34. Littleton, Colorado
  35. Lone Tree, Colorado
  36. Longmont, Colorado
  37. Parker, Colorado
  38. Pueblo, Colorado
  39. Thornton, Colorado
  40. Aventura, Florida
  41. Fleming Island, Florida
  42. Jacksonville Beach, Florida
  43. Jacksonville, Florida
  44. Jacksonville, Florida
  45. Jacksonville, Florida
  46. Jacksonville, Florida
  47. Jacksonville, Florida
  48. Saint Augustine, Florida
  49. Atlanta, Georgia
  50. Atlanta, Georgia
  51. Atlanta, Georgia
  52. Atlanta, Georgia
  53. Atlanta, Georgia
  54. Atlanta, Georgia
  55. Atlanta, Georgia
  56. Newnan, Georgia
  57. Arlington Heights, Illinois
  58. Chicago, Illinois
  59. Chicago, Illinois
  60. Chicago, Illinois
  61. Chicago, Illinois
  62. Chicago, Illinois
  63. Niles, Illinois
  64. Baton Rouge, Louisiana
  65. Columbus, Mississippi
  66. Grenada, Mississippi
  67. Jackson, Mississippi
  68. Jackson, Mississippi
  69. New Albany, Mississippi
  70. Oxford, Mississippi
  71. Southaven, Mississippi
  72. Starkville, Mississippi
  73. Florham Park, New Jersey
  74. Phillipsburg, New Jersey
  75. Phillipsburg, New Jersey
  76. Toledo, Ohio
  77. Toledo, Ohio
  78. Portland, Oregon
  79. Portland, Oregon
  80. Portland, Oregon
  81. Tualatin, Oregon
  82. Allentown, Pennsylvania
  83. Allentown, Pennsylvania
  84. Bethlehem, Pennsylvania
  85. Bethlehem, Pennsylvania
  86. Coaldale, Pennsylvania
  87. Easton, Pennsylvania
  88. Easton, Pennsylvania
  89. Gettysburg, Pennsylvania
  90. Greensburg, Pennsylvania
  91. Monroeville, Pennsylvania
  92. Philadelphia, Pennsylvania
  93. Pittsburgh, Pennsylvania
  94. Pittsburgh, Pennsylvania
  95. Pittsburgh, Pennsylvania
  96. Pittsburgh, Pennsylvania
  97. Quakertown, Pennsylvania
  98. Stroudsburg, Pennsylvania
  99. Uniontown, Pennsylvania
  100. Washington, Pennsylvania
  101. Sioux Falls, South Dakota
  102. Bartlett, Tennessee
  103. Collierville, Tennessee
  104. Harrogate, Tennessee
  105. Jefferson City, Tennessee
  106. Knoxville, Tennessee
  107. Knoxville, Tennessee
  108. Memphis, Tennessee
  109. Morristown, Tennessee
  110. Newport, Tennessee
  111. Allen, Texas
  112. Arlington, Texas
  113. Arlington, Texas
  114. Austin, Texas
  115. Austin, Texas
  116. Austin, Texas
  117. Dallas, Texas
  118. Denton, Texas
  119. Houston, Texas
  120. Houston, Texas
  121. Houston, Texas
  122. Houston, Texas
  123. Irving, Texas
  124. Irving, Texas
  125. Irving, Texas
  126. McKinney, Texas
  127. New Braunfels, Texas
  128. Plano, Texas
  129. Round Rock, Texas
  130. San Antonio, Texas
  131. Chesapeake, Virginia
  132. Hampton, Virginia
  133. Newport News, Virginia
  134. Norfolk, Virginia
  135. Virginia Beach, Virginia
  136. Vancouver, Washington
  137. Vancouver, Washington
  138. Madison, Wisconsin
  139. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
Official Title  ICMJE A RANDOMIZED, DOUBLE-BLIND PHARMACOKINETIC STUDY OF PF-05280014 PLUS TAXOTERE (REGISTERED) AND CARBOPLATIN VERSUS HERCEPTIN (REGISTERED) PLUS TAXOTERE (REGISTERED) AND CARBOPLATIN FOR THE NEOADJUVANT TREATMENT OF PATIENTS WITH OPERABLE HER2-POSITIVE BREAST CANCER
Brief Summary The current study will compare PK, efficacy, safety, and immunogenicity of PF-05280014 (Trastuzumab-Pfizer) in combination with Taxotere® and Carboplatin (Paraplatin) versus Herceptin® (Trastuzumab-EU) approved in the EU in combination with Taxotere® and Carboplatin (Paraplatin) in patients with operable HER2 positive, breast cancer in the neoadjuvant setting. The hypothesis to be tested in this study is the percentage of patients with steady state Cycle 5 Ctrough (Cycle 6 pre-dose) >20 µg/mL of trastuzumab-Pfizer is similar to EU-approved trastuzumab, using a margin of -12.5%.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Early Breast Cancer
Intervention  ICMJE
  • Biological: PF-05280014
    Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
  • Drug: Taxotere®
    Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
    Other Name: docetaxel
  • Drug: Paraplatin®
    Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
    Other Name: carboplatin
  • Biological: Trastuzumab-EU
    Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
Study Arms  ICMJE
  • Experimental: PF-05280014
    Interventions:
    • Biological: PF-05280014
    • Drug: Taxotere®
    • Drug: Paraplatin®
  • Active Comparator: Herceptin®
    Interventions:
    • Biological: Trastuzumab-EU
    • Drug: Taxotere®
    • Drug: Paraplatin®
Publications * Lammers PE, Dank M, Masetti R, Abbas R, Hilton F, Coppola J, Jacobs I. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer. 2018 Aug;119(3):266-273. doi: 10.1038/s41416-018-0147-1. Epub 2018 Jul 13.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 28, 2016)		226
Original Estimated Enrollment  ICMJE
 (submitted: July 8, 2014)		220
Actual Study Completion Date  ICMJE March 9, 2016
Actual Primary Completion Date March 9, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed HER2 overexpressing invasive breast cancer.
  • Plan for definitive surgical resection of breast tumor (i.e., lumpectomy or mastectomy, and sentinel node (SN) biopsy or axillary lymph node dissection (ALND).
  • Plan for neoadjuvant chemotherapy.
  • Measurable disease in the breast after diagnostic biopsy, defined as longest diameter ? 2.0 cm.

Exclusion Criteria:

  • Bilateral breast cancer.
  • Inflammatory breast cancer.
  • Presence of known distant metastases.
  • Received prior treatment, including chemotherapy, endocrine therapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belarus,   Czechia,   Hungary,   Italy,   Poland,   Russian Federation,   Serbia,   Slovakia,   Ukraine,   United States
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT02187744
Other Study ID Numbers  ICMJE B3271004
REFLECTIONS B327-04
2013-004679-11 ( EudraCT Number )
REFLECTIONS (B327-04) ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP